Piotr Wysocki: Cannabis and cannabinoid in adult cancer patients

Piotr Wysocki recently shared on LinkedIn:

“ASCO guidelines devoted to cannabis and cannabinoid use in adult cancer patients have been published in the Journal of Clinical Oncology.

Selected recommendations are summarized below:

• Cancer patients should have access to unbiased, evidence-based cannabis and/or cannabinoid educational resources.
• Clinicians should routinely ask their patients about cannabis use (or consideration of use) to either guide care or provide patients with appropriate resources.
• Clinicians should recommend against the use of cannabis and/or cannabinoids as anti-cancer treatment (outside of clinical trials).
• Clinicians should recommend against the use of cannabis and/or cannabinoids in place of anti-cancer treatment.
• Cancer patients who experience refractory nausea or vomiting despite adequate prophylaxis may augment their antiemetic regimen with dronabinol, nabilone, or a quality-controlled oral 1:1 THC:CBD extract.
• Patients should not exceed 300 mg or more per day of oral CBD to manage symptoms due to a lack of proven efficacy and risk for reversible liver enzyme abnormalities.
• Evidence remains insufficient to recommend for or against cannabis and/or cannabinoids in managing cancer treatment-related toxicities or symptoms (including cancer pain).”

Source: Piotr Wysocki/LinkedIn

Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.

His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.